Skip to main content
Erschienen in: Cellular Oncology 4/2014

01.08.2014 | Original Paper

ARID3B expression in primary breast cancers and breast cancer-derived cell lines

verfasst von: Ayse Selcen Oguz Erdogan, Nihan Ozdemirler, Merve Oyken, Murat Alper, Ayse Elif Erson-Bensan

Erschienen in: Cellular Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

ARID3B (AT-rich interaction domain 3) is a member of the family of ARID proteins, which constitutes evolutionarily conserved transcription factors implicated in normal development, differentiation, cell cycle regulation and chromatin remodeling. In addition, ARID3B has been linked to cellular immortalization, epithelial-mesenchymal transition (EMT) and tumorigenesis. Given the emerging role of ARID3B in tumor development, we examined its expression in primary patient-derived breast cancer samples and breast cancer-derived cell lines.

Methods

Immunohistochemistry (IHC) was used to detect ARID3B expression in 63 formalin-fixed paraffin-embedded (FFPE) invasive breast cancer samples. In addition, a panel of 6 (estrogen receptor-positive and -negative, ERBB2-positive and -negative) breast cancer-derived cell lines and immortalized non-tumorigenic epithelial breast cells were used for ARID3B expression analysis using RT-PCR. Specific primers and Western blotting were used to detect ARID3B isoforms.

Results

Using IHC, nuclear, cytoplasmic and low levels of membranous ARID3B staining were detected in all 63 primary invasive breast tumors. Nuclear ARID3B staining positively correlated with estrogen receptor (ER) status and negatively correlated with tumor grade, mitotic index and ERBB2 status of the patients. Increased nuclear expression of ARID3B was confirmed in breast cancer-derived cell lines expressing ERα. In addition, two out of three ERBB2-positive breast cancer cell lines were found to lack full length ARID3B. Three ARID3B isoforms were found to be present in normal breast epithelial cells as well as in breast cancer cells.

Conclusion

We report a positive correlation between ER positivity and nuclear ARID3B expression in primary breast cancers, along with a negative correlation with the ERBB2 status. Very similar correlations were noted in breast cancer-derived cell lines. Since in the recent past ARID3B expression has increasingly been related to cancer-associated proteins and microRNAs, knowledge on ARID3B expression and function may be instrumental for gaining further insight into potentially important cancer-related networks.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat D. Wilsker, A. Patsialou, P.B. Dallas, E. Moran, ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 13, 95–106 (2002)PubMed D. Wilsker, A. Patsialou, P.B. Dallas, E. Moran, ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 13, 95–106 (2002)PubMed
2.
Zurück zum Zitat C. Lin, W. Song, X. Bi, J. Zhao, Z. Huang, Z. Li, J. Zhou, J. Cai, H. Zhao, Recent advances in the ARID family: focusing on roles in human cancer. Oncol. Targets Ther. 7, 315–324 (2014) C. Lin, W. Song, X. Bi, J. Zhao, Z. Huang, Z. Li, J. Zhou, J. Cai, H. Zhao, Recent advances in the ARID family: focusing on roles in human cancer. Oncol. Targets Ther. 7, 315–324 (2014)
3.
Zurück zum Zitat S. Numata, P.P. Claudio, C. Dean, A. Giordano, C.M. Croce, Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Res. 59, 3741–3747 (1999)PubMed S. Numata, P.P. Claudio, C. Dean, A. Giordano, C.M. Croce, Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Res. 59, 3741–3747 (1999)PubMed
4.
Zurück zum Zitat K. Kobayashi, T. Era, A. Takebe, L.M. Jakt, S. Nishikawa, ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res. 66, 8331–8336 (2006)PubMedCrossRef K. Kobayashi, T. Era, A. Takebe, L.M. Jakt, S. Nishikawa, ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res. 66, 8331–8336 (2006)PubMedCrossRef
5.
Zurück zum Zitat J.C. Casanova, V. Uribe, C. Badia-Careaga, G. Giovinazzo, M. Torres, J.J. Sanz-Ezquerro, Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements. Development 138, 1195–1205 (2011)PubMedCrossRef J.C. Casanova, V. Uribe, C. Badia-Careaga, G. Giovinazzo, M. Torres, J.J. Sanz-Ezquerro, Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements. Development 138, 1195–1205 (2011)PubMedCrossRef
7.
Zurück zum Zitat K.D. Cowden Dahl, R. Dahl, J.N. Kruichak, L.G. Hudson, The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11, 1208–1215 (2009)PubMedCentralPubMed K.D. Cowden Dahl, R. Dahl, J.N. Kruichak, L.G. Hudson, The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11, 1208–1215 (2009)PubMedCentralPubMed
8.
Zurück zum Zitat S. Akhavantabasi, A. Sapmaz, S. Tuna, A.E. Erson-Bensan, miR-125b targets ARID3B in breast cancer cells. Cell Struct. Funct. 37, 27–38 (2009)CrossRef S. Akhavantabasi, A. Sapmaz, S. Tuna, A.E. Erson-Bensan, miR-125b targets ARID3B in breast cancer cells. Cell Struct. Funct. 37, 27–38 (2009)CrossRef
9.
Zurück zum Zitat A. Erson, E. Petty, miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol. Ther. 8, 2317–2322 (2009)PubMedCrossRef A. Erson, E. Petty, miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol. Ther. 8, 2317–2322 (2009)PubMedCrossRef
10.
Zurück zum Zitat R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. (Dordr.) 36, 1–7 (2013)CrossRef R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. (Dordr.) 36, 1–7 (2013)CrossRef
11.
Zurück zum Zitat E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention. Cell. Oncol. (Dordr.) 37, 167–178 (2014)CrossRef E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention. Cell. Oncol. (Dordr.) 37, 167–178 (2014)CrossRef
13.
14.
Zurück zum Zitat S. Joseph, V.E. Deneke, K.D. Cowden Dahl, ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death. PLoS One 7, e42159 (2012)PubMedCentralPubMedCrossRef S. Joseph, V.E. Deneke, K.D. Cowden Dahl, ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death. PLoS One 7, e42159 (2012)PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat B.H. Akman, T. Can, A.E. Erson-Bensan, Estrogen-induced upregulation and 3′-UTR shortening of CDC6. Nucleic Acids Res. 40, 10679–10688 (2012)PubMedCentralPubMedCrossRef B.H. Akman, T. Can, A.E. Erson-Bensan, Estrogen-induced upregulation and 3′-UTR shortening of CDC6. Nucleic Acids Res. 40, 10679–10688 (2012)PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat S. Akhavantabasi, H.B. Akman, A. Sapmaz, J. Keller, E.M. Petty, A.E. Erson, USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm. Genome 21, 388–397 (2010)PubMedCrossRef S. Akhavantabasi, H.B. Akman, A. Sapmaz, J. Keller, E.M. Petty, A.E. Erson, USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm. Genome 21, 388–397 (2010)PubMedCrossRef
17.
Zurück zum Zitat W.J. Kent, C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler, D. Haussler, The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002)PubMedCentralPubMedCrossRef W.J. Kent, C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler, D. Haussler, The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002)PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat R. Metivier, G. Penot, R.P. Carmouche, M.R. Hubner, G. Reid, S. Denger, D. Manu, H. Brand, M. Kos, V. Benes, F. Gannon, Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J. 23, 3653–3666 (2004)PubMedCentralPubMedCrossRef R. Metivier, G. Penot, R.P. Carmouche, M.R. Hubner, G. Reid, S. Denger, D. Manu, H. Brand, M. Kos, V. Benes, F. Gannon, Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J. 23, 3653–3666 (2004)PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat D. McDonald, G. Carrero, C. Andrin, G. de Vries, M.J. Hendzel, Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations. J. Cell Biol. 172, 541–552 (2006)PubMedCentralPubMedCrossRef D. McDonald, G. Carrero, C. Andrin, G. de Vries, M.J. Hendzel, Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations. J. Cell Biol. 172, 541–552 (2006)PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, S.L. Deming, J. Geradts, M.C. Cheang, T.O. Nielsen, P.G. Moorman, H.S. Earp, R.C. Millikan, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006)PubMedCrossRef L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, S.L. Deming, J. Geradts, M.C. Cheang, T.O. Nielsen, P.G. Moorman, H.S. Earp, R.C. Millikan, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006)PubMedCrossRef
21.
Zurück zum Zitat G. Scott, A. Goga, D. Bhaumik, C. Berger, C. Sullivan, C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–1486 (2007)PubMedCrossRef G. Scott, A. Goga, D. Bhaumik, C. Berger, C. Sullivan, C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–1486 (2007)PubMedCrossRef
22.
Zurück zum Zitat S.J. Samyesudhas, L. Roy, K.D. Cowden Dahl, Differential expression of ARID3B in normal adult tissue and carcinomas. Gene 10, 174–180 (2014)CrossRef S.J. Samyesudhas, L. Roy, K.D. Cowden Dahl, Differential expression of ARID3B in normal adult tissue and carcinomas. Gene 10, 174–180 (2014)CrossRef
Metadaten
Titel
ARID3B expression in primary breast cancers and breast cancer-derived cell lines
verfasst von
Ayse Selcen Oguz Erdogan
Nihan Ozdemirler
Merve Oyken
Murat Alper
Ayse Elif Erson-Bensan
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 4/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0185-5

Weitere Artikel der Ausgabe 4/2014

Cellular Oncology 4/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie